Bolt Biotherapeutics to Participate in Upcoming September Investor Conferences
September 02 2021 - 8:00AM
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology
company pioneering a new class of immuno-oncology agents that
combine the targeting precision of antibodies with the power of
both the innate and adaptive immune systems, today announced that
management will present a corporate update and conduct meetings
with the investment community at four upcoming virtual investor
conferences in September:
- Citi’s 16th Annual BioPharma Virtual
ConferenceMeetings with investors on Wednesday, Sept.
8
- Wells Fargo Virtual Healthcare
ConferencePresentation on Thursday, Sept. 9, at 12:30 p.m.
PT (3:20 p.m. ET)
- Morgan Stanley 19th
Annual Global Healthcare ConferenceFireside chat
on Monday, Sept. 13, at 12:30 p.m. PT (3:30 p.m. ET)
- 2021 Cantor Fitzgerald Virtual Global Healthcare
ConferencePresentation on Thursday, Sept. 30, at 11:00
a.m. PT (2:00 p.m. ET)
A live webcast of the presentations will be available on the
Events and Presentations page of Bolt’s website at www.boltbio.com.
Archived replays will be available for 30 days following the
event.
About Bolt Biotherapeutics, Inc.Bolt
Biotherapeutics, Inc. is a clinical-stage biotechnology company
pioneering a new class of immuno-oncology agents that combine the
targeting precision of antibodies with the power of both the innate
and adaptive immune systems Bolt’s proprietary Boltbody™
Immune-stimulating Antibody Conjugate (ISAC) approach uses
immunostimulants to engage and activate myeloid cells that directly
kill tumor cells. This leads to the conversion of immunologically
“cold” tumors to “hot” tumors. Bolt’s lead candidate, BDC-1001, is
a Boltbody ISAC comprised of a HER2-targeting biosimilar of
trastuzumab conjugated to one of Bolt’s proprietary TLR7/8 agonists
for the treatment of patients with HER2-expressing solid tumors.
Bolt is also advancing additional Boltbody ISAC product candidates
targeting CEA and PD-L1. For more information, visit
https://www.boltbio.com/.
Investor Relations and Media Contacts:Karen L.
BergmanVice President, Communications and Investor RelationsBolt
Biotherapeutics, Inc.650-665-9295kbergman@boltbio.com
Sarah McCabeStern Investor Relations,
Inc.212-362-1200sarah.mccabe@sternir.com
Maggie Beller or David SchullRusso Partners,
LLC646-942-5631maggie.beller@russopartnersllc.comdavid.schull@russopartnersllc.com
Bolt Biotherapeutics (NASDAQ:BOLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bolt Biotherapeutics (NASDAQ:BOLT)
Historical Stock Chart
From Apr 2023 to Apr 2024